Advances in pharmacogenomics of selective serotonin reuptake inhibitors
10.13699/j.cnki.1001-6821.2018.02.026
- VernacularTitle:选择性5-羟色胺再摄取抑制药的药物基因组学研究现状
- Author:
Shan ZHOU
1
;
Min HUANG
;
Xue-Ding WANG
Author Information
1. 中山大学药学院
- Keywords:
selective serotonin reuptake inhibitor;
efficacy;
pharmacogenomics
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(2):188-192
- CountryChina
- Language:Chinese
-
Abstract:
At present,depression is mainly treated by drugs,while the remission rate of the first-line antidepressant selective serotonin reuptake inhibitor is only about 60％-70％.Many studies showed that the gene polymorphisms might be important factors influencing inter individual differences in drug reactions.Recent pharmacogenomics researches suggested that some related genes may affect the efficacy of selective serotonin reuptake inhibitor in the world.Here we briefly reviewed the pharmacogenomic research progress of several commonly used selective serotonin reuptake inhibitors,such as fluoxetine and sertraline from the aspect of clinical efficacy.
